Key facts
- This page summarizes Nikolay Savchuk's Form 4 filing for Lomond Therapeutics Holdings, Inc..
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 05 Nov 2024, 18:00.
Nikolay Savchuk - 01 Nov 2024 Form 4 Insider Report for Lomond Therapeutics Holdings, Inc.
- Reporting relationship
- President and COO, Director
- Issuer ticker
- N/A
- Reported as of
- 01 Nov 2024
- Net transaction value
- +$9,999,997
- SEC form
- 4
- Accepted by SEC
- 05 Nov 2024, 18:00:55 UTC
- Prior SEC filing
- 03 Apr 2024
- Next SEC filing
- 27 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Nikolay Savchuk
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Nikolay Savchuk filed Form 4 for Lomond Therapeutics Holdings, Inc. on 05 Nov 2024.
Change
- Previous filing in this sequence was filed on 03 Apr 2024.
- Current net transaction value: +$9,999,997.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
No ticker
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $1,724,998
- Shares
- +539,062
- Change %
- Price
- $3.20
- Shares after
- 539,062
- Date
- 01 Nov 2024
- Ownership
- By TPAV, LLC
- Footnotes
- F1, F2, F6
No ticker
transaction
Common Stock
Conversion of derivative security
- Transaction value
- $2,499,998
- Shares
- +694,444
- Change %
- +129%
- Price
- $3.60
- Shares after
- 1,233,506
- Date
- 01 Nov 2024
- Ownership
- By TPAV, LLC
- Footnotes
- F1, F3, F6
No ticker
transaction
Common Stock
Award
- Transaction value
- $5,775,000
- Shares
- +1,443,750
- Change %
- +117%
- Price
- $4.00
- Shares after
- 2,677,256
- Date
- 01 Nov 2024
- Ownership
- By TPAV, LLC
- Footnotes
- F1, F4, F6
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
No ticker
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,258,000
- Change %
- Price
- $0.000000
- Shares after
- 1,258,000
- Date
- 01 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,258,000
- Exercise price
- $1.30
- Footnotes
- F5
No ticker
transaction
Derivative
Simple Agreement for Future Equity
Conversion of derivative security
- Transaction value
- $0
- Shares
- +539,062
- Change %
- Price
- $0.000000
- Shares after
- 0
- Date
- 01 Nov 2024
- Ownership
- By TPAV, LLC
- Underlying class
- Common Stock
- Underlying amount
- 539,062
- Exercise price
- Footnotes
- F1, F2, F6
No ticker
transaction
Derivative
Simple Agreement for Future Equity
Conversion of derivative security
- Transaction value
- $0
- Shares
- +694,444
- Change %
- Price
- $0.000000
- Shares after
- 0
- Date
- 01 Nov 2024
- Ownership
- By TPAV, LLC
- Underlying class
- Common Stock
- Underlying amount
- 694,444
- Exercise price
- Footnotes
- F1, F3, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On November 1, 2024, the Issuer closed the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of November 1, 2024, by and among Venetian-1 Acquisition Corp., a Delaware corporation (the "Parent"), Lomond Acquisition Corp., a Delaware corporation (the "Acquisition Subsidiary"), and Lomond Therapeutics, Inc. ("Legacy Lomond") (the "Merger"), pursuant to which, upon consummation of the Merger, all of the outstanding shares Legacy Lomond common stock were converted into shares of the Issuer's Common Stock on a 1:1 basis pursuant to the terms of the Merger Agreement (the "Merger"). Immediately following the closing of the Merger, the Issuer completed a private placement financing (the "Offering").
Footnote F2
These shares are held of record by TPAV, LLC issued upon the conversion of an outstanding simple agreement for future equity ("SAFE") in the amount of $1,725,000, which converted upon the closing of the Merger and the Offering at 80% of the per share price in the Offering and had no expiration date.
Footnote F3
These shares are held of record by TPAV, LLC issued upon the conversion of a SAFE in the amount of $2,500,000, which converted upon the closing of the Merger and the Offering at 90% of the per share price in the Offering and had no expiration date.
Footnote F4
Represents shares held directly by TPAV, LLC issued upon the closing of the Offering.
Footnote F5
The options are subject to a service-based vesting requirement, which shall be satisfied over a four-year period with 1/48th of the options vesting monthly after November 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.
Footnote F6
The reported shares are owned directly by TPAV, LLC, a limited liability company of which the reporting person is the sole manager on its Board of Managers. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.